The application for a Hong Kong IPO filed by Hunan Mabgeek Biotech Co., Ltd. - B (Mabgeek Biotech) on July 14, 2025, has lapsed after the standard six-month period, becoming invalid as of January 14, 2026. China International Capital Corporation (CICC) acted as the sole sponsor for the listing application. According to the prospectus, Mabgeek Biotech is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of innovative biologics to address unmet medical needs in allergic and autoimmune diseases, as well as other inflammatory and immune disorders. Since its establishment in 2016, the company has independently developed a robust pipeline comprising eight innovative candidate products. These include the core product MG-K10, key products MG-014 and MG-013, along with five other candidate products. All of these products are next-generation long-acting antibodies discovered and developed through the company's proprietary technology platform.